Fig. 2
From: Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
Imaging before panel A receiving anti-HER2 directed therapy and 6 months after panel B receiving trastuzumab, pertuzumab, and gemcitabine. Patient is a 47-year-old woman with NRG1 fusion (VTCN1/NRG1), KRAS wild-type pancreatic cancer (whose disease had previously progressed on gemcitabine-based therapy). Panel A represents a scout film from PET imaging that shows innumerable hepatic lesions (red arrows), splenic metastases (blue arrows), normal tracer in the kidneys, brain, and urinary bladder before receiving anti-HER2 therapy. Panel B shows decreased in the number of liver lesions (red arrow), diminished splenic metastases, and redemonstrates normal tracer in the kidneys, brain, and urinary bladder, 6 months after receiving trastuzumab, pertuzumab, and gemcitabine